Artículos de revistas
Lactococcus lactis NCDO2118 produces anti-hypertensive GABA and exerts acute hypotensive in spontaneously hypertensive rats
Fecha
2016-11Registro en:
Azevedo, Vasco; Souza Santos, Robson Augusto; Pereira Figueiredog, Henrique Cesar; Venanzif, Franco; Ghose, Preetam; Barhd, Debmalya; et al.; Lactococcus lactis NCDO2118 produces anti-hypertensive GABA and exerts acute hypotensive in spontaneously hypertensive rats; Knowledge Enterprises Incorporated; Medical Research Archives; 4; 7; 11-2016; 1-21
2375-1916
2375-1924
CONICET Digital
CONICET
Autor
Diniz Luerce Saraiva, Tessália
Etelvinob, Gisele Maia
Oliveirab, Mariana
Severiano de Sousaa, Cassiana
de Azevedo, Marcela Santiago Pacheco
de Moreno, Maria Alejandra
Leblanc, Jean Guy Joseph
Barhd, Debmalya
Ghose, Preetam
Venanzif, Franco
Pereira Figueiredog, Henrique Cesar
Souza Santos, Robson Augusto
Azevedo, Vasco
Resumen
Gamma (y)-aminobutyric acid (GABA) is a molecule with nutraceutical interest since it is recognized for its health-promoting properties such as hypotensive effects. Some lactic acid bacteria (LAB) have been shown to be able to produce GABA. In the present investigation, Lactococcus (L.) lactis NCDO2118, a probiotic LAB, was cultured in a medium supplemented with different concentration of glutamate, the substrate for GABA production. This strain was evaluated in SHRSP (Spontaneously Hypertensive Stroke-Prone Rats) to assess its hypotensive effect. The evaluation showed that GABA production is variable depending on the glutamate concentration and incubation time and that the increased GABA production potentiates its hypotensive effect. This work demonstrates that L. lactis NCDO 2118 could be used as a tool for developing health-promoting foods, such as those enriched with GABA as an interesting and novel pharmacological strategy.